Outlook Therapeutics(OTLK)
$0.41+0.05 (+13.06%)
OTLK
Outlook Therapeutics stock drug pipeline
$0.41
At close:+0.05 (+13.06%)
Want to see OTLK full AI Analyst Report?
Outlook Therapeutics (OTLK) Drug Pipeline
1,839 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Bevacizumab, Ranibizumab | Age-Related Macular Degeneration, Neovascular Age-Related Macular Degeneration, Wet Macular Degeneration | Phase III | Completed | A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD) | Dec 19, 2023 | ― |
| Bevacizumab | Diabetic Macular Edema, Neovascular Age-Related Macular Degeneration, Age-Related Macular Degeneration, Wet Macular Degeneration, Brvo - Branch Retinal Vein Occlusion | Phase III | Active Not Recruiting | A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders | Oct 28, 2021 | ― |
| Bevacizumab | Diabetic Macular Edema, Age-Related Macular Degeneration, Neovascular Age-Related Macular Degeneration, Wet Macular Degeneration, Brvo - Branch Retinal Vein Occlusion | Phase III | Completed | A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders | Aug 13, 2020 | ― |
| Bevacizumab, Ranibizumab | Age-Related Macular Degeneration, Neovascular Age-Related Macular Degeneration, Wet Macular Degeneration | Phase III | Completed | A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) | Feb 14, 2019 | ― |
| Bevacizumab, Ranibizumab | Age-Related Macular Degeneration, Neovascular Age-Related Macular Degeneration, Wet Macular Degeneration | Phase III | Completed | A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) | Feb 06, 2019 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Bevacizumab, Ranibizumab | Phase III | Age-Related Macular Degeneration, Neovascular Age-Related Macular Degeneration, Wet Macular Degeneration | Completed | A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD) | Dec 19, 2023 | ― |
| Bevacizumab | Phase III | Diabetic Macular Edema, Neovascular Age-Related Macular Degeneration, Age-Related Macular Degeneration, Wet Macular Degeneration, Brvo - Branch Retinal Vein Occlusion | Active Not Recruiting | A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders | Oct 28, 2021 | ― |
| Bevacizumab | Phase III | Diabetic Macular Edema, Age-Related Macular Degeneration, Neovascular Age-Related Macular Degeneration, Wet Macular Degeneration, Brvo - Branch Retinal Vein Occlusion | Completed | A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders | Aug 13, 2020 | ― |
| Bevacizumab, Ranibizumab | Phase III | Age-Related Macular Degeneration, Neovascular Age-Related Macular Degeneration, Wet Macular Degeneration | Completed | A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) | Feb 14, 2019 | ― |
| Bevacizumab, Ranibizumab | Phase III | Age-Related Macular Degeneration, Neovascular Age-Related Macular Degeneration, Wet Macular Degeneration | Completed | A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) | Feb 06, 2019 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Outlook Therapeutics (OTLK) have in its pipeline
Outlook Therapeutics OTLK is currently developing the following drugs: Bevacizumab, Ranibizumab, Bevacizumab. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

